Development of molecular targeted therapy of multiple sclerosis on the basis of membrane protein microarray analysis and gene interactions

基于膜蛋白微阵列分析和基因相互作用开发多发性硬化症分子靶向治疗

• 批准号: 22390178
• 负责人: KIRA Jun-ichi
• 金额: $ 12.06万
• 依托单位: Kyushu University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22390178/
• 关键词: 多発性硬化症; 遺伝子間相互作用; サイトカイン; 自己抗体; 視神経脊髄炎; HLA; IL2RA; 自己抗体プロファイル; バイオマーカー; IL7RA

In Japanese demyelinating disease, whereas DRB1*0901 is a disease resi stance gene regardless of the disease phenotype, disease susceptibility gene revealed that depending on the disease phenotype. IL7RA gene, a disease susceptibility gene in Western Caucasian, was shown to be a disease susceptibility gene in Japanese MS. The IL2RA gene, may contribute to disease susceptibility only when it interacts with HLA-DRB1*1501 or HLA-DRB1*0405. By using a cell-free protein synthesis system, LUZP1 is obtained as a self-antigen significantly more in CIDP than Balo disease, SOX6 was obtained as a self-antigen significantly more in MS than Balo disease and CIDP. The high sensitivity anti-AQP4 antibody assay revealed that IgG1 is associated with disease duration, and there was a reverse correlation between the spinal cord lesion length IgG2 .

在日本脱髓鞘病中，无论疾病表型如何，DRB1*0901都是抗病基因，而疾病易感基因表明，这取决于疾病表型。 IL7RA基因是西方白种人的疾病易感基因，已被证明是日本MS的疾病易感基因。 IL2RA 基因仅当与 HLA-DRB1*1501 或 HLA-DRB1*0405 相互作用时才可能导致疾病易感性。通过使用无细胞蛋白质合成系统，在CIDP中获得的自体抗原LUZP1显着多于Balo病，在MS中获得的SOX6显着多于Balo病和CIDP作为自体抗原。高灵敏度抗AQP4抗体测定显示IgG1与疾病持续时间相关，并且脊髓病变长度IgG2之间存在负相关。

项目成果

Wall-eyed bilateral internuclear ophthalmoplegia (WEBINO) syndrome in a patient with neuromyelitis optica spectrum disorder and anti-aquaporin-4 antibody

• DOI: 10.1177/1352458510391690
• 发表时间: 2011-07-01
• 期刊: MULTIPLE SCLEROSIS JOURNAL
• 影响因子: 5.8
• 作者: Shinoda, Koji;Matsushita, Takuya;Kira, Jun-ichi
• 通讯作者: Kira, Jun-ichi

Impact and characteristics of quality of life in Japanese patients with multiple sclerosis

• DOI: 10.1007/s11136-010-9725-2
• 发表时间: 2011-02-01
• 期刊: QUALITY OF LIFE RESEARCH
• 影响因子: 3.5
• 作者: Kikuchi, Hiromi;Mifune, Nobuhiro;Kikuchi, Seiji
• 通讯作者: Kikuchi, Seiji

MSとNMOの治療の将来展望

MS 和 NMO 治疗的未来前景

• 发表时间: 2013
• 期刊: Pharma Medica
• 作者: 渡邉充;吉良潤一
• 通讯作者: 吉良潤一

日本人多発性硬化症(MS)患者の増加は軽症のHLA-DRB1^*0405アリル保有MS患者の増加による

日本多发性硬化症（MS）患者数量的增加是由于具有轻度HLA-DRB1^*0405等位基因的MS患者的增加。

• 发表时间: 2011
• 作者: 吉良潤一;ら
• 通讯作者: ら

Immunopathology of Multiple Sclerosis, Neuromyelitis optica, and Balo's Disease

多发性硬化症、视神经脊髓炎和 Balo 病的免疫病理学

• 发表时间: 2010
• 作者: Yokoyama A;Ficara F;Murphy MJ;Meisel C;Naresh A;Kitabayashi I;Cleary ML;Kira J
• 通讯作者: Kira J